Sacituzumab Govitecan 180 mg in India: A Breakthrough in Cancer Therapy
Introduction: Cancer treatment has evolved extraordinarily over the years, with new therapies contributing hope to patients facing challenging diagnosis. One such innovative treatment is Sacituzumab Govitecan 180 mg, a embattled therapy mainly used for certain types of advanced cancers, particularly metastatic triple-negative breast cancer (mTNBC). What is Sacituzumab Govitecan? Sacituzumab Govitecan 180 mg in India is a medicine conjugate consisting of two key components: an antibody and a chemotherapy agent. The antibody exclusively targets the Trop-2 protein, which is extremely expressed in various cancers, mainly in breast cancer cells. Once the antibody binds to the cancer cells, the attached chemotherapy drug (SN-38) is delivered directly to the tumor site, plummeting the impact on healthy cells and improving the effectiveness of the treatment. This pioneering approach helps to reduce the side effects typically associated with traditional chemotherapy while ensuring the drug is